| Literature DB >> 25629685 |
D Braida1, F R Guerini2, L Ponzoni3, I Corradini4, S De Astis5, L Pattini6, E Bolognesi2, R Benfante4, D Fornasari7, M Chiappedi8, A Ghezzo9, M Clerici10, M Matteoli11, M Sala7.
Abstract
Synaptosomal-associated protein of 25 kDa (SNAP-25) is involved in different neuropsychiatric disorders, including schizophrenia and attention-deficit/hyperactivity disorder. Consistently, SNAP-25 polymorphisms in humans are associated with hyperactivity and/or with low cognitive scores. We analysed five SNAP-25 gene polymorphisms (rs363050, rs363039, rs363043, rs3746544 and rs1051312) in 46 autistic children trying to correlate them with Childhood Autism Rating Scale and electroencephalogram (EEG) abnormalities. The functional effects of rs363050 single-nucleotide polymorphism (SNP) on the gene transcriptional activity, by means of the luciferase reporter gene, were evaluated. To investigate the functional consequences that SNAP-25 reduction may have in children, the behaviour and EEG of SNAP-25(+/-) adolescent mice (SNAP-25(+/+)) were studied. Significant association of SNAP-25 polymorphism with decreasing cognitive scores was observed. Analysis of transcriptional activity revealed that SNP rs363050 encompasses a regulatory element, leading to protein expression decrease. Reduction of SNAP-25 levels in adolescent mice was associated with hyperactivity, cognitive and social impairment and an abnormal EEG, characterized by the occurrence of frequent spikes. Both EEG abnormalities and behavioural deficits were rescued by repeated exposure for 21 days to sodium salt valproate (VLP). A partial recovery of SNAP-25 expression content in SNAP-25(+/-) hippocampi was also observed by means of western blotting. A reduced expression of SNAP-25 is responsible for the cognitive deficits in children affected by autism spectrum disorders, as presumably occurring in the presence of rs363050(G) allele, and for behavioural and EEG alterations in adolescent mice. VLP treatment could result in novel therapeutic strategies.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25629685 PMCID: PMC4312830 DOI: 10.1038/tp.2014.136
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Distribution of five SNAP-25 SNPs (rs363050(A/G), rs363039(G/A) rs363043(C/T), rs3746544(T/G)) and rs1051312(T/C) genotypes in children with autism spectrum disorders
| AA (18) | 41.4 (5.5) | 5.3 (0.5) | 2.9 (0.6) | 3.5 (1.1) | 0.44 | 0.56 |
| AG (18) | 37.2 (6.1) | 2.7 (0.5) | 2.4 (0.7) | 4.5 (1.1) | 0.11 | 0.89 |
| GG (8) | 37.8 (7.2) | 3.2 (0.7) | 2.6 (0.5) | 3.1 (1.0) | 0.75 | 0.25 |
| df=2, c2=10.7, | df=2, F=2.5, | df=2, F=2.4, | df=2, F=6.8, | df=2, c2=10.7, | ||
| GG (18) | 40.8 (5.4) | 3.0 (0.5) | 2.9 (0.6) | 3.5 (1.0) | 0.44 | 0.56 |
| GA (22) | 37.4 (6.1) | 2.8 (0.6) | 2.5 (0.6) | 4.3 (1.2) | 0.23 | 0.77 |
| AA (4) | 39.6 (9.9) | 3.0 (0.8) | 2.7 (0.5) | 3.0 (0.8) | 0.75 | 0.25 |
| df=2, F=1.5, | df=2, F=0.7, | df=2, F=2.1, | df=2, F=3.2, | df=2, c2=4.8, | ||
| CC (20) | 37.5 (6.7) | 2.9 (0.6) | 2.6 (0.6) | 3.9 (1.0) | 0.40 | 0.60 |
| CT (22) | 39.9 (5.4) | 2.8 (0.5) | 2.8 (0.5) | 3.9 (1.4) | 0.32 | 0.68 |
| TT (2) | 45.0 (8.5) | 3.5 (0.7) | 3.5 (0.7) | 3.5 (0.7) | 0.50 | 0.50 |
| df=2, F=1.8, | df=2, F=1.2, | df=2, F=1.2, | df=2, F=0.1, | df=2, c2=0.5, | ||
| TT (17) | 40.6 (6.6) | 2.9 (0.5) | 2.8 (0.8) | 3.6 (1.2) | 0.35 | 0.65 |
| TG (23) | 38.1 (6.2) | 2.9 (0.6) | 2.5 (0.5) | 4.1 (1.2) | 0.30 | 0.70 |
| GG (4) | 37.7 (4.6) | 3.1 (0.2) | 2.9 (0.5) | 3.5 (1.0) | 0.75 | 0.25 |
| df=2, F=0.9, | df=2, F=0.3, | df=2, F=1.3, | df=2, F=0.9, | df=2, c2=2.9, | ||
| TT (25) | 39.5 (5.8) | 2.9 (0.5) | 2.6 (0.5) | 3.8 (0.7) | 0.40 | 0.60 |
| TC (17) | 37.1 (6.1) | 2.8 (0.6) | 2.5 (0.7) | 3.9 (1.3) | 0.35 | 0.65 |
| CC (2) | 48.7 (3.2) | 3.5 (0.7) | 3.0 (0.1) | 4.5 (1.1) | 01.0 | |
| df=2, F=3.2, | df=2, F=1.4, | df=2, F=3.1, | df=2, F=0.4, | df=2, c2=1.3, | ||
Abbreviations: ANOVA, analysis of variance; ASD, autism spectrum disorder; CARS, Childhood Autism Rating Scale; df, degrees of freedom; SNP, single-nucleotide polymorphism; SNAP, synaptosomal-associated protein.
Children with ASD (N=44) were classified based on the CARS, autism, hyperactivity, degree of cognitive impairment and cognitive-level frequencies. ANOVA test was applied to mean score distribution of CARS, autism and hyperactivity, and cognitive scores are shown. Cognitive-level frequencies were classified as follows: 1: profound mental retardation; 2: severe mental retardation; 3: mild mental retardation; 4: moderate mental retardation; 5: borderline level; 6: normal functioning.
Distribution of the rs363050(A/G), rs363039(G/A) and rs363043(C/T), rs3746544(TG) and rs1051312(TC) genotypes evaluated in children with autism spectrum disorders
| P- | ||||||
|---|---|---|---|---|---|---|
| AA (18) | 15 (0.83) | 2 (0.11) | 1 (0.06) | |||
| AG (18) | 14 (0.77) | 3 (0.17) | 1 (0.06) | |||
| GG (8) | 6 (0.74) | 1 (0.13) | 1 (0.13) | |||
| 3 | 0.73 | 0.95 | ||||
| GG (18) | 16 (0.89) | 1 (0.05) | 1 (0.05) | |||
| GA (22) | 16 (0.73) | 4 (0.18) | 2 (0.09) | |||
| AA (4) | 3 (0.75) | 0 | 1 (0.25) | |||
| 3 | 3.58 | 0.46 | ||||
| CC (20) | 15 (0.75) | 3 (0.15) | 2 (0.10) | |||
| CT (22) | 18 (0.82) | 3 (0.14) | 1 (0.04) | |||
| TT (2) | 2 (1.00) | 0 | 0 | |||
| 3 | 1.07 | 0.89 | ||||
| TT (17) | 15 (0.88) | 1 (0.06) | 1 (0.06) | |||
| TG (23) | 17 (0.74) | 4 (0.17) | 2 (0.09) | |||
| GG (4) | 3 (0.75) | 1 (0.25) | 0 | |||
| 3 | 2.04 | 0.63 | ||||
| TT (25) | 20 (0.80) | 4 (0.16) | 1 (0.04) | |||
| TC (17) | 13 (0.76) | 2 (0.12) | 2 | −12 | ||
| CC (2) | 2 (1.00) | 0 | 0 | |||
| 3 | 1.58 | 0.81 | ||||
Abbreviations: df, degrees of freedom; EEG, electroencephalogram; SEIZ, seizures.
Children (44) were classified based on the degree of cognitive impairment and on the degree of cortical electrical dysfunction. Cortical dysfunction: lack of EEG abnormalities and absence of seizures (EEG−/SEIZ−), presence of EEG abnormalities without seizures (EEG+/SEIZ−), seizures without interictal EEG abnormalities (EEG−/SEIZ+) and presence of both EEG abnormalities and seizure (EEG+/SEIZ+). N=number of patients. Values are expressed as frequencies. P-value with Bonferroni correction.
Figure 1Functional effect of rs363050 single-nucleotide polymorphism (SNP). SNP rs363050 contains a regulatory element leading to synaptosomal-associated protein of 25 kDa (SNAP-25) expression decrease. (a) The presence of the parental allele (A), when cloned in single copy upstream the thymidine kinase (TK) promoter (construct rs363050A-TK-luc) did not increase the activity of the heterologous TK promoter (white bar vs black bar), whereas the presence of the minor allele (G) (construct rs363050G-TK-luc) significantly affected by 33% the activity of the promoter (F(4,10)=234.8, P=0.001, one-way analysis of variance (ANOVA)). (b and c) The region surrounding the rs363050 and rs363043 SNP was cloned in four and three concatenated copies, respectively. Left: schematic illustration of the constructs. The black boxes represent the HSV-TK promoter, the white boxes in panel A the 747 bp region of SNAP-25 gene intron 1 spanning rs363050 SNP, the grey oval represent the Firefly luciferase reporter gene (luc). The black cross indicates the (A) to (G) change; the arrows indicate the transcription start site. Right: luciferase assays. SH-SY5Y cells were transiently transfected with the constructs shown on the left. The bars show the transcriptional activity of the constructs expressed as a relative expression level of luciferase normalized to that of renilla with respect to the TK-luc construct (=1), and expressed as mean values±s.d. of at least three independent experiments performed in triplicate. The three asterisks indicate a statistically significant difference between rs363050A and rs363050G constructs (one-way ANOVA). In a, $$$ indicates a statistically significant difference between TK-luc/pGL4 basic and TK-luc-rs363050A construct (one-way ANOVA, P<0.001); in b it indicates a statistically significant difference between four rs363050A and rs363050G copy constructs (one-way ANOVA, P<0.001).
Figure 2Behavioural profile and synaptosomal-associated protein of 25 kDa (SNAP-25) expression of SNAP-25 and SNAP-25 mice evaluated 24 h after sodium valproate salt (VLP) (1 mg ml−1) or water exposure for 21 days. (a) The mean (±s.e.m.) of horizontal movements recorded every 10 min in the last 2 h of basal (pre) and every hour after amphetamine (4 mg kg−1) treatment for 3 h (two-way analysis of variance (ANOVA) (genotype as a between-subject factor: F(3,126)=4.06; P=0.01; time as a within-subject factor: F(3,126)=30.95; P=0.0001; treatment × genotype interaction: F(9,126)=20.10, P<0.0001). ***P<0.001 vs SNAP-25+/+ water-exposed mice, same interval; °°P<0.01, °°°P<0.001 vs corresponding pre; $$P<0.01, $$$P<0.001 vs SNAP-25− water-exposed mice, same interval (Bonferroni post hoc test). (b) Conditioned taste aversion (CTA). Mice were exposed to saccharin solution (0.5%) followed, 1 h later, by a malaise-inducing injection of LiCl (0.14 M, 2% body weight, intraperitoneally). A lack of CTA was shown in SNAP-25 mice (genotype as a between-subject factor: F(1,36)=73.38; P<0.0001; treatment as a within-subject factor: F(1,36)=4.82, P=0.03; genotype × treatment: F(1,36) =27.84; P<0.0001, two-way repeated measure ANOVA). ***P<0.001 compared with SNAP-25+/+ water-exposed mice; &P<0.05 compared with SNAP− water-exposed mice (Bonferroni post hoc test). (c–d) Difference score (mean±s.e.m.) in terms of time difference spent in the chamber associated with the never-seen-before mouse and empty cage or familiar mouse (preference for social novelty test). There was a difference among groups for sociability: (genotype as a between-subject factor: F(1,36)=42.94; P<0.0001; treatment as a within-subject factor: F(1,36)=33.93; P<0.0001; genotype × treatment: F(1,36)=16.88; P=0.0002, two-way ANOVA for repeated measures of variance). There was a difference among groups for social novelty (genotype as a between-subject factor: F(1,36)=188.8; P<0.0001; treatment as a within-subject factor: F(1,36)=32.09; P<0.0001; genotype × treatment: F(1,36)=6.62; P=0.001, two-way repeated measure of variance). ***P<0.001 compared with water-exposed SNAP-25 mice; °°P<0.01, °°°P<0.001 compared with SNAP water-exposed mice (Bonferroni post hoc test). (e) Object recognition task. Discrimination index (mean±s.e.m.), evaluated 120 min after mice were presented with a familiar and a new object, was different among groups (two-way ANOVA: genotype as a between-subject factor: F(1,36)=0.50, P=0.48; treatment as a within-subject factor: F(1,36)=5.16; P=0.02; genotype × treatment: F(1,36)=100.9, P=0.0001). *P<0.05, ***P<0.001 compared with water-exposed SNAP-25 mice; °°°P<0.001 vs SNAP-25 water exposed (Bonferroni post hoc test). (f) SNAP-25 expression in the hippocampus and prefrontal cortex of 6-week-old mice pre-exposed to water or VLP for 21 days. Western blotting analysis and relative quantitation, carried out in SNAP-25− water-exposed mice, showed reduced SNAP-25 expression, significantly only in hippocampus, and a recovery of SNAP-25 expression after VLP treatment (genotype as a between-subject factor: F(1,17)=9.66, P=0.006; treatment as a within-subject factor F(1,17)=2.56; P=0.12; genotype × treatment F(1,17)=7.53; P=0.01). n=5/6 for each group (genotype as a between-subject factor: F(1,16)=7.01, P=0.001; treatment as a within-subject factor F(1,16)=0.88; P=0.36; genotype × treatment F(1,16)=0.88; P=0.35). n=5/6 for each group. No significant changes in prefrontal cortex were shown **P<0.001 compared with SNAP-25 water-exposed mice; &P<0.05 vs SNAP-25 water exposed (Bonferroni test).
Figure 3Synaptosomal-associated protein of 25 kDa (SNAP-25+/−) mice showed abnormal electroencephalogram (EEG), which was rescued by VLP at least for 1 week. (a) Spike activity (mean±s.e.m.) in basal conditions evaluated every hour during the 24-h recording. **P<0.01 compared with SNAP-25+/+ mice. (b) Effect of exposure to sodium valproate salt (VLP) or water for 21 days evaluated in two representative mice for 2 h, evaluated 24 h after the end of the exposure. Two-way analysis of variance (ANOVA) showed differences among the groups (genotype as a between-subject factor: F(1,40)=62,51, P<0.0001; time as a within-subject factor: F(4,40)=6,415; P<0.001; genotype × time F(4,40)=6.39; P<0.001). (c) Quantitative analysis of mean (±s.e.m.) number of spikes evaluated every week for 3 weeks after exposure cessation. ***P<0.001 vs baseline SNAP-25− mice. °°P<0.05, °°°P<0.001 vs corresponding SNAP-25+/+ mice (Bonferroni post hoc test). (d) Western blotting analysis and relative quantification of SNAP-25 levels in SNAP-25+/− hippocampi evaluated immediately and 3 weeks after VLP withdrawal. N=5 for each genotype. **P <0,0038 (Student's t-test).